NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

Core Viewpoint - NervGen Pharma Corp. has appointed Dr. Adam Rogers as President and CEO, reflecting the Board's confidence in his leadership and vision for the company's future in neuroreparative therapeutics for spinal cord injury [1][2][3] Company Leadership - Dr. Rogers has been recognized for his decisive execution during his tenure as Interim CEO, including the successful Nasdaq listing and positioning of NVG-291 for late-stage development [2][3] - The Board believes Dr. Rogers embodies the leadership qualities necessary for advancing novel therapies, emphasizing his background as a physician and biotech executive [3] Company Mission and Product Development - NervGen's mission is to transform the lives of individuals with spinal cord injuries by enabling the nervous system to repair itself [6][7] - The lead therapeutic candidate, NVG-291, has shown durable improvement in function and quality of life in clinical studies and is preparing for a Phase 3 trial [7] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA, highlighting its potential in addressing significant unmet medical needs [7] Stock Options and Compensation - In connection with Dr. Rogers' appointment, the company granted 717,891 stock options, with specific vesting schedules and exercise prices [3]